EA201070295A1 - Лечение рака легких - Google Patents

Лечение рака легких

Info

Publication number
EA201070295A1
EA201070295A1 EA201070295A EA201070295A EA201070295A1 EA 201070295 A1 EA201070295 A1 EA 201070295A1 EA 201070295 A EA201070295 A EA 201070295A EA 201070295 A EA201070295 A EA 201070295A EA 201070295 A1 EA201070295 A1 EA 201070295A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung cancer
treatment
inhibit
treat
subject
Prior art date
Application number
EA201070295A
Other languages
English (en)
Inventor
Синтия В. Татхилл
Original Assignee
Сиклоун Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиклоун Фармасьютикалз, Инк. filed Critical Сиклоун Фармасьютикалз, Инк.
Publication of EA201070295A1 publication Critical patent/EA201070295A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Иммуномодуляторное соединение, вводимое для лечения, предупреждения, ингибирования или уменьшения рака легких у субъекта.
EA201070295A 2007-08-23 2008-08-21 Лечение рака легких EA201070295A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95753007P 2007-08-23 2007-08-23
PCT/US2008/009932 WO2009025830A1 (en) 2007-08-23 2008-08-21 Treatment of lung cancer

Publications (1)

Publication Number Publication Date
EA201070295A1 true EA201070295A1 (ru) 2010-10-29

Family

ID=40378469

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070295A EA201070295A1 (ru) 2007-08-23 2008-08-21 Лечение рака легких

Country Status (14)

Country Link
US (1) US20110189305A1 (ru)
EP (1) EP2192835A4 (ru)
JP (1) JP2010536854A (ru)
KR (1) KR20100063078A (ru)
CN (1) CN101842009A (ru)
AU (1) AU2008289522A1 (ru)
BR (1) BRPI0815772A2 (ru)
CA (1) CA2697261A1 (ru)
EA (1) EA201070295A1 (ru)
MX (1) MX2010002046A (ru)
NZ (1) NZ584065A (ru)
UA (1) UA98508C2 (ru)
WO (1) WO2009025830A1 (ru)
ZA (1) ZA201001876B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090119897A (ko) 2007-02-13 2009-11-20 사이클론 파아머슈티컬 인코오퍼레이티드 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법
RU2519738C2 (ru) * 2011-12-12 2014-06-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации Способ лечения рака легкого

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких

Also Published As

Publication number Publication date
JP2010536854A (ja) 2010-12-02
ZA201001876B (en) 2010-11-24
UA98508C2 (ru) 2012-05-25
AU2008289522A1 (en) 2009-02-26
EP2192835A4 (en) 2010-11-10
CN101842009A (zh) 2010-09-22
EP2192835A1 (en) 2010-06-09
US20110189305A1 (en) 2011-08-04
BRPI0815772A2 (pt) 2014-09-30
NZ584065A (en) 2012-03-30
KR20100063078A (ko) 2010-06-10
WO2009025830A1 (en) 2009-02-26
CA2697261A1 (en) 2009-02-26
MX2010002046A (es) 2010-05-03

Similar Documents

Publication Publication Date Title
EA201170521A1 (ru) Новые соединения
EA201270247A1 (ru) Способы применения с-мет-модуляторов
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
EA201171367A1 (ru) Винилиндазолильные соединения
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
EA201400178A1 (ru) Лечение рака молочной железы
EA201170832A1 (ru) Пуриновые соединения
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PA8850801A1 (es) Compuestos útiles para inhibir chk1
PH12015501088A1 (en) Dimeric compounds
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
EA201490199A8 (ru) Терапевтические способы
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения